Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Hypoxic-ischemic encephalopathy
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Apr 24, 2024
Q1 2024 quarterly activity and cash flow report
Apr 23, 2024
Trofinetide accepted for Priority Review by Health Canada
Apr 23, 2024
Appendix 4G
Apr 23, 2024
2023 Annual Report to shareholders
Apr 08, 2024
Application for quotation of securities - NEU
Mar 12, 2024
Application for quotation of securities - NEU
Feb 29, 2024
2023 Results webinar
Feb 29, 2024
Neuren reports profit of $157 million for 2023
Feb 29, 2024
Appendix 4E and 2023 full year accounts
Feb 29, 2024
Neuren 2023 results investor webinar on 29 February 2024
Previous
1
2
3
4
5
6
7
Next
